QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
NASDAQ:DRMA

Dermata Therapeutics - DRMA Stock Forecast, Price & News

Notice: Trading of Dermata Therapeutics halted at 02:51 PM EST due to "LULD pause".
$1.68
+0.34 (+25.37%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.26
▼
$1.98
50-Day Range
$1.34
▼
$51.52
52-Week Range
$1.26
▼
$23.52
Volume
1.65 million shs
Average Volume
239,824 shs
Market Capitalization
$1.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

Dermata Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
138.1% Upside
$4.00 Price Target
Short Interest
Healthy
2.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of Dermata Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

See Top Rated MarketRank™ Stocks Here

DRMA stock logo

About Dermata Therapeutics (NASDAQ:DRMA) Stock

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.

Receive DRMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DRMA Stock News Headlines

March 20, 2023 | finance.yahoo.com
Dermata Therapeutics Announces Closing of $5.0 Million Public Offering
March 20, 2023 | finance.yahoo.com
Dermata Therapeutics Announces Closing of $5.0 Million Public Offering
March 23, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
March 16, 2023 | marketwatch.com
Dermata Therapeutics Up 24% After Boosting Size of Offering
March 16, 2023 | finance.yahoo.com
Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering
February 28, 2023 | seekingalpha.com
DRMA Dermata Therapeutics, Inc.
February 21, 2023 | finance.yahoo.com
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results
December 30, 2022 | benzinga.com
Thinking about buying stock in Dermata Therapeutics, Silo Pharma, IQIYI, First Wave BioPharma, or I-Mab?
March 23, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
December 30, 2022 | benzinga.com
Why Dermata Therapeutics Stock Is Trading 100% Higher Today
December 30, 2022 | benzinga.com
Why Dermata Therapeutics Shares Are Trading Higher By Over 100%; Here Are 21 Stocks Moving Premarket
November 10, 2022 | finance.yahoo.com
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
September 7, 2022 | finanznachrichten.de
Dermata Therapeutics: Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 6, 2022 | finance.yahoo.com
Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference
August 25, 2022 | finanznachrichten.de
Dermata Therapeutics: Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase
August 24, 2022 | finance.yahoo.com
Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase
August 16, 2022 | finance.yahoo.com
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
June 13, 2022 | finance.yahoo.com
Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea
May 23, 2022 | finanznachrichten.de
Dermata Therapeutics: Dermata to Present at the H.C. Wainwright Global Investment Conference
May 23, 2022 | finance.yahoo.com
Dermata to Present at the H.C. Wainwright Global Investment Conference
May 16, 2022 | finance.yahoo.com
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
April 25, 2022 | finance.yahoo.com
Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
April 21, 2022 | seekingalpha.com
Dermata Therapeutics launches $5M securities offering
April 21, 2022 | finance.yahoo.com
Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
March 28, 2022 | seekingalpha.com
Dermata Therapeutics GAAP EPS of -$2.43 beats by $0.75
March 28, 2022 | finance.yahoo.com
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results
March 24, 2022 | finance.yahoo.com
Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference
See More Headlines
Receive DRMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DRMA Company Calendar

Last Earnings
2/21/2023
Today
3/23/2023
Next Earnings (Estimated)
5/15/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DRMA
CUSIP
N/A
CIK
1853816
Web
www.dermatarx.com
Phone
858-800-2543
Fax
N/A
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+1,067.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($14.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-9,610,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-124.00%
Return on Assets
-106.83%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.52
Quick Ratio
7.52

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.82 per share
Price / Book
0.18

Miscellaneous

Outstanding Shares
770,000
Free Float
490,000
Market Cap
$1.05 million
Optionable
Not Optionable
Beta
0.61

Key Executives

  • Mr. Gerald T. Proehl (Age 63)
    Founder, Pres, CEO & Chairman
    Comp: $135.91k
  • Mr. David F. Hale (Age 73)
    Co-Founder & Lead Independent Director
    Comp: $27.19k
  • Ms. Kyri K. Van Hoose CPA (Age 43)
    M.B.A., Sr. VP & CFO
    Comp: $265.05k
  • Dr. Christopher J. Nardo M.P.H. (Age 57)
    Ph.D., Sr. VP & Chief Devel. Officer
    Comp: $356.4k
  • Mr. Sean Proehl
    Sr. Director of Legal & Bus. Devel.
  • Dr. Maria Bedoya Toro Munera M.B.A. (Age 70)
    Ph.D., Sr. VP of Regulatory Affairs & Quality Assurance

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













DRMA Stock - Frequently Asked Questions

Should I buy or sell Dermata Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dermata Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DRMA shares.
View DRMA analyst ratings or view top-rated stocks.

What is Dermata Therapeutics' stock price forecast for 2023?

2 equities research analysts have issued twelve-month price targets for Dermata Therapeutics' shares. Their DRMA share price forecasts range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next year. This suggests a possible upside of 192.0% from the stock's current price.
View analysts price targets for DRMA or view top-rated stocks among Wall Street analysts.

How have DRMA shares performed in 2023?

Dermata Therapeutics' stock was trading at $6.5440 at the beginning of 2023. Since then, DRMA stock has decreased by 79.1% and is now trading at $1.37.
View the best growth stocks for 2023 here.

When is Dermata Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our DRMA earnings forecast.

How were Dermata Therapeutics' earnings last quarter?

Dermata Therapeutics, Inc. (NASDAQ:DRMA) released its earnings results on Tuesday, February, 21st. The company reported ($1.92) earnings per share for the quarter.

When did Dermata Therapeutics' stock split?

Dermata Therapeutics's stock reverse split on Tuesday, March 14th 2023. The 1-16 reverse split was announced on Tuesday, March 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

When did Dermata Therapeutics IPO?

(DRMA) raised $18 million in an initial public offering on Friday, August 13th 2021. The company issued 2,571,428 shares at $7.00 per share.

What is Dermata Therapeutics' stock symbol?

Dermata Therapeutics trades on the NASDAQ under the ticker symbol "DRMA."

Who are Dermata Therapeutics' major shareholders?

Dermata Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Raymond James Financial Services Advisors Inc. (1.15%).

How do I buy shares of Dermata Therapeutics?

Shares of DRMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dermata Therapeutics' stock price today?

One share of DRMA stock can currently be purchased for approximately $1.37.

How much money does Dermata Therapeutics make?

Dermata Therapeutics (NASDAQ:DRMA) has a market capitalization of $1.05 million. The company earns $-9,610,000.00 in net income (profit) each year or ($14.24) on an earnings per share basis.

How can I contact Dermata Therapeutics?

The official website for the company is www.dermatarx.com. The company can be reached via phone at 858-800-2543 or via email at sproehl@dermatarx.com.

This page (NASDAQ:DRMA) was last updated on 3/23/2023 by MarketBeat.com Staff